EntryPoint Capital’s HilleVax HLVX Stock Holding History

EntryPoint Capital’s Portfolio HLVX Stock Details HLVX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-4,802	Closed	-$79.9K	–	1205
2024 Q1	$79.9K	Buy	+4,802	New	+$76.8K	0.07%	538

Other funds holding HLVX

FLSM

Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return

TPC

Takeda Pharmaceutical Company Tokyo, Japan $16.4M AUM 195.92% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

Carlyle Group Washington, District of Columbia $10.6B AUM 11.25% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Catalys Pacific Tokyo, Japan $231M AUM 83.19% 1-Year Est. Return

EntryPoint Capital's HLVX Position: Q2 2024 in Review

EntryPoint Capital sold out of HilleVax (HLVX) in Q2 2024, closing a stake of 4,802 shares — an estimated $79.9K sold.

EntryPoint Capital first reported a position in HLVX in Q1 2024 and held it in 1 quarter. The position peaked at $79.9K in Q1 2024. 93 funds tracked by Wall St. Rank hold HLVX as of Q2 2024.

EntryPoint Capital reported no remaining HilleVax position as of Q2 2024 after selling out during the quarter.
EntryPoint Capital sold 4,802 HilleVax shares in Q2 2024, an estimated $79.9K.
EntryPoint Capital first reported a position in HilleVax in Q1 2024 and held it in 1 quarter.
EntryPoint Capital's HilleVax position peaked at $79.9K in Q1 2024.
93 funds tracked by Wall St. Rank held HilleVax as of Q2 2024.

Based on EntryPoint Capital's 13F filing for Q2 2024, filed 13 Aug 2024.